Samsung Biologics unveiled its new drug screening service, Samsung Organoids, on Monday. The company aims to secure early partnerships by collaborating with client companies from the initial stages of drug candidate discovery.
Drawing on its extensive experience in Good Manufacturing Practice (GMP) operations, validated by 359 manufacturing approvals from key global regulators like the FDA and EMA, Samsung Biologics plans to deliver premium organoid services. These services will feature high-quality sample processing and flawless data management, setting a new standard in the field.
The company’s initial focus will be on screening anticancer drug candidates using patient-derived cancer organoids. This approach aims to overcome the limitations of traditional cell or animal models, which often struggle with low patient similarity, high costs, and ethical concerns.
Organoids are mini-organ models created by culturing stem cells or tissue-derived cells in three dimensions. They’ve gained traction in the market due to their cost-effectiveness and high patient similarity rate of 85%, which enables more precise and rapid assessment of drug efficacy and toxicity compared to conventional methods.
Research and Markets projects the global organoid market to expand from 1 billion USD in 2022 to 3.3 billion USD by 2030, growing at an annual rate of 22%. The FDA’s recent push to reduce animal testing and promote alternatives, such as organoids, in April, is expected to accelerate this growth further.
With this new service launch, Samsung Biologics is ramping up its strategy to become a global top-tier CDMO. The company plans to invest in portfolio expansion, focusing on three key growth areas: boosting production capacity, diversifying its portfolio, and expanding its global footprint. Beyond organoids, this includes development in antibodies, antibody-drug conjugates (ADCs), and adeno-associated viruses (AAVs).
John Rim, CEO of Samsung Biologics, stated that the company’s rapid and accurate screening services, available from the earliest stages of development, are designed to significantly reduce the clients’ risks while accelerating the development timelines. He added that they’re committed to developing cutting-edge technologies and services to meet their clients’ diverse needs and ensure client satisfaction.